Prostate Cancer

ProstaScint Approval Recommended for Metastatic Disease Risk in Cancer Patients

Published in Cancer Weekly, August 5th, 1996

Cytogen Corp., Princeton, New Jersey, reported that the Medical Imaging Drug Advisory Committee (MIDAC) to the U.S. Food and Drug Administration (FDA) recommended that ProstaScint be approved for use in patients with prostate cancer in whom there is a high clinical suspicion of occult metastatic disease.

The information provided by ProstaScint should be considered in conjunction with other available diagnostic information. Thomas J. McKearn, Cytogen, stated, "Existing non-invasive diagnostic agents such as CT and MRI add little to the patient's or the physician's ability to predict whether the cancer has spread to areas outside the prostatic bed and into the patient's...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1996-08-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry